Personalis, Inc.’s Post

🎉 Exciting News! 🎉 I am thrilled to announce the publication of our latest article, "Rituximab as a Therapeutic Strategy in Hemophagocytic Lymphohistiocytosis: Efficacy, Outcomes, and Survival—Insights From a Systematic Review," in the American Journal of Clinical Oncology. This comprehensive review delves into Rituximab's potential as a therapeutic option for Hemophagocytic Lymphohistiocytosis (HLH), analyzing its efficacy, patient outcomes, and overall survival rates. Key Findings: - Of 783 identified records, 24 studies were included in the final analysis. - Rituximab was typically administered at 375 mg/m², with varying doses and treatment frequency. - Clinical response, often seen within one month, was assessed by improvements in clinical symptoms and laboratory findings. - Survival rates post-treatment displayed a wide range, with instances of complete remission and disease-free periods, as well as reports of relapse and mortality. Our findings provide valuable insights that could significantly influence treatment strategies and improve patient care. I extend my heartfelt gratitude to my co-authors, collaborators, and everyone who contributed to this study. Your support and expertise were instrumental in bringing this research to fruition. You can read the full article here: [Link to Article](https://lnkd.in/eBh-rj6r) #research #publication #hematology #oncology #rituximab #HLH #systematicreview #patientcare #clinicaloncology

The wide range of topics in the issue includes:   A tribute: Oncology  ✔️ Major inequalities in Europe  ✔️ New treatment options for multiple myeloma  ✔️ Early diagnosis of pancreatic cancer  ✔️ New findings in triple negative breast cancer  ✔️ Prostate cancer: An explosion of cases expected  ✔️ Why so many young people are dying of cancer    🛈 Still:    New drugs threaten health  What European Drugs Centre research shows    Half of innovative drugs will not come to Greece  IQVIA study on the SFEI    At a critical crossroads for the NHS  What was said at the 15th Pharma & Health Conference    Attikon Hospital: Pioneering medical education laboratory  Learning augmented reality (AR) and artificial intelligence (AI)      👉 Find out about FULL PACK or DIGI PACK subscriptions: https://lnkd.in/d6B2457a  Virus.com.gr #health #pharma #hematology #cancer #healthcare #patients #corporate #magazine 

Embracing New Horizons in Hemato Oncology: A Journey Through Diverse Life Sciences✨💫✅ From academics to industry and health tech, and from autoimmune disorders to diabetes research, and now to the Hemato Oncology department... this career shift has allowed me to explore the diverse domains of life sciences. This journey has significantly broadened my perspective on human disorders and the development of targeted therapies. Devoted to cancer research now and excited for the new challenges and opportunities ahead in Hemato Oncology! #research #leukemia #CareerGrowth #LifeSciences #CancerResearch #HematoOncology #HealthcareInnovation #TargetedTherapies #HealthTech #ResearchAndDevelopment #IndustryTransition #MedicalScience

The wide range of topics in the issue includes:   A tribute: Oncology  ✔️ Major inequalities in Europe  ✔️ New treatment options for multiple myeloma  ✔️ Early diagnosis of pancreatic cancer  ✔️ New findings in triple negative breast cancer  ✔️ Prostate cancer: An explosion of cases expected  ✔️ Why so many young people are dying of cancer    🛈 Still:    New drugs threaten health  What European Drugs Centre research shows    Half of innovative drugs will not come to Greece  IQVIA study on the SFEI    At a critical crossroads for the NHS  What was said at the 15th Pharma & Health Conference    Attikon Hospital: Pioneering medical education laboratory  Learning augmented reality (AR) and artificial intelligence (AI)      👉 Find out about FULL PACK or DIGI PACK subscriptions: https://lnkd.in/d6B2457a  #health #pharma #hematology #cancer #healthcare #patients #corporate #magazine 

**Oral Cancer Topic No. 3: Basaloid Squamous Cell Carcinoma** 🔬 Exploring Basaloid Squamous Cell Carcinoma: Unveiling Insights in Oncology 🔬 1. **Understanding the Unique Histology**: Basaloid Squamous Cell Carcinoma (BSCC) presents with distinctive histological characteristics, posing diagnostic challenges and necessitating a nuanced approach in clinical management. 2. **Unraveling Molecular Mechanisms**: Delving into the molecular landscape of BSCC, we're deciphering the intricate interplay of genetic alterations and signaling pathways driving its pathogenesis, offering potential targets for precision therapies. 3. **Identifying Biomarkers for Early Detection**: By elucidating specific biomarkers associated with BSCC, we aim to enhance early detection strategies, enabling timely interventions and improved patient outcomes. 4. **Exploring Therapeutic Avenues**: Through collaborative research efforts, we're exploring novel therapeutic modalities tailored to target BSCC's unique vulnerabilities, striving to optimize treatment efficacy and minimize adverse effects. 5. **Empowering Healthcare Professionals**: By disseminating knowledge and insights on BSCC, we empower healthcare professionals with the tools and resources needed to navigate its complexities and deliver personalized care to patients. Together, let's advance the frontier of oncology and bring hope to those affected by BSCC. #Oncology #Research #BSCC #CancerAwareness #MedicalScience #Giridihdentist #India

It's exciting to have contributed two chapters on ovarian cancer diagnostics, prognosis, prediction and therapeutics in this amazing #book alongside some of the world leading experts in the field. Peritoneal Tumor Microenvironment of Cancers on Cancer Hallmarks: Perspectives of Translational Medicine provides readers with cutting-edge knowledge on tumor microenvironment. By exploring multiple aspects on tumor microenvironment, it gives an integrative insight on cancer diseases ranging from diagnosis to prediction of prognosis and individualized treatment. This book is a valuable resource for cancer researchers, oncologists, medical doctors, and several members of #biomedical field who want to understand the complex microenvironment of peritoneal tumors. You can grab a copy via this link: https://lnkd.in/gz7URsZJ I highly recommend this book to all individuals hoping to start a career in cancer research 📊. #pathology #labmed #blackexcellence

📆In just one month, we will be hosting the VI Conference on Translational Research on Urological Tumours at the BCIN Badalona, presented in a dynamic hybrid format—both virtual and in-person. 🔍The primary goal of this conference is to delve into the intricacies of urological tumours through the lens of translational and clinical research. Over the course of these two days, 20 esteemed national and international experts in urological tumour treatment and research will provide comprehensive updates and reviews on pivotal research lines. Topics include mechanisms of therapy resistance, exploration of new potential biomarkers, breakthroughs in immunotherapy, innovative preclinical tools for translational research, and promising therapies in urologic tumours. 👥 The conference is designed for professionals engaged in the diagnosis and treatment of urological tumours, as well as translational researchers with a keen interest in this area of oncology. Don't miss this opportunity to connect with leading experts, gain valuable insights, and stay at the forefront of urological tumours research! 🆓 Register for free at: jornadasurobdn@outlook.es Germans Trias i Pujol Research Institute (IGTP); Catalan Institute of Oncology #UrologicalTumours #TranslationalResearch #OncologyConference #MedicalResearch #prostatecancer #bladdercancer #kidneycancer #immunotherapy #biomarkers #oncologyresearch #oncology #oncología #BCIN

Mount Sinai researchers are advancing the science of early detection biomarkers by studying small RNA expression signatures from circulating extracellular vesicles. This new study will compare the effectiveness of liquid biopsy to the current standard—abdominal ultrasound and serum alpha-fetoprotein—for detecting early-stage hepatocellular carcinoma. “Our goal is to develop a minimally invasive, blood-only surveillance biomarker for hepatocellular carcinoma that would significantly increase patient compliance by making the process easier than ever before,” says Dr. Augusto Villanueva, Associate Professor of Medicine (Hematology and Medical Oncology, and Liver Diseases) at Icahn School of Medicine at Mount Sinai. “We know that if we’re able to detect a tumor in its early stages, we can cure patients in more than 70 percent of cases.” Learn more: https://bit.ly/3XMiBDS #CancerResearch #LiquidBiopsy #HepatocellularCarcinoma #MountSinai

🧬 Advancing Neuroblastoma Treatment Through Pharmacogenetics A pivotal study by Gladys Olivera, Andrea Urtasun, Luis Sendra, Salvador F Aliño, Yania Yáñez, Vanessa Segura, Pablo Gargallo, Pablo Berlanga, Victoria Castel, Adela Cañete, María José Herrero explores the role of pharmacogenetics in the treatment of neuroblastoma, marking significant strides in personalized precision medicine. 🔬 Study Insights Emphasizes the integration of pharmacogenetics in clinical management Focus on tailoring therapies for pediatric cancer patients, specifically in neuroblastoma Discusses current state-of-the-art genetic variants and their clinical applications 📚 Essential Reading for Oncologists and Researchers 🎓 Earn 1.0 CME Credit: https://lnkd.in/dUZ2yaJS #PediatricCancer #Pharmacogenetics #Oncology #CME

#HISTOLOGY >> Placenta stained via #Immunohistochemistry (#IHC) for PD-L1 protein (programmed cell death ligand 1). Recent research highlights the crucial role of PD-L1 in #cancer #immunotherapy, emphasizing its significance as a predictive #biomarker for treatment response and patient prognosis. MLM Medical Labs' capabilities in exploring PD-L1 expression dynamics facilitate current research efforts and make us a great partner for #oncology projects. Elucidating the complex interactions involving PD-L1 in the tumor microenvironment sheds light on immune evasion mechanisms, paving the way for innovative therapeutic interventions targeting immune checkpoints. Let’s combine our efforts to enhance therapeutic efficacy and patient outcomes worldwide. Reach out directly to learn more or to start a conversation > Marlena Jelec MD, MBA >> https://lnkd.in/gXPPU4d3